News Focus
News Focus
icon url

harry crumb

07/07/17 4:31 PM

#2732 RE: Apophis #2731

agree 1000%
icon url

Apophis

07/07/17 4:32 PM

#2733 RE: Apophis #2731

Based on a $2500 dosage and 300,000 patients in Europe this could be 750 million in gross sales?



This stock will begin to explode once revenue begins. EPS $3-4 and a PE of 13 = over $40/share




yup, counting the chickens before they hatch.......

icon url

n3m3sis

07/07/17 5:21 PM

#2735 RE: Apophis #2731

You Feel Bad????? .................

For the Shorts?????.......

DONT.

One of the reasons drugs cost so much money is the fact of the hell that many micro cap and small cap bios have to go through with short selling their stocks, driving their pps down. Thus having to enact reverse splits, stock offerings and such like.

Many go bust, that novel breakthrough therapy they were working on never seeing the light of day.
Others go through the shizen, get bought out or merge with Big P or another company and finally their solutions to unmet needs get released. Because of the expenditure required to get to that point a premium is placed on their drugs once they get approval, either from the FDA or the EC. Phase 2/3/trials and NDA's cost a hell of a lot, especially when your pps is being damaged (sometimes irreparably) by short sellers and you have no income to speak of.
I only hope and pray that none of those parasites need the drug(s)of a company that they have driven out of business with their quest for short term profits.

Feel sorry for shorts? NO WAY!!

rant done.

GO GO $AVEO